Loading…
Whistleblower Protection Extension Act of 2017
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
89pct
146d open
vs 7,393 other HR bills in the 115th — cohort avg 50d
Whistleblower Protection Extension Act of 2017 This bill permanently extends the requirement for inspectors general (IGs) to designate a Whistleblower Protection Ombudsman to educate agency employees about prohibitions on retaliation, and the rights and remedies against retaliation, for protected disclosures. The bill renames the Whistleblower Protection Ombudsman as the Whistleblower Protection Coordinator. It also expands the responsibilities of a Whistleblower Protection Coordinator to include the following: educating employees about specific rights and remedies (e.g., the means by which an employee may seek review of an allegation of reprisal); assisting the IG in promoting the timely and appropriate handling and consideration of protected disclosures and allegations of reprisal; and assisting the IG in facilitating communication and coordination with other relevant persons and entities regarding timely and appropriate handling and consideration of protected disclosures, allegations of reprisal, and other general matters. A Whistleblower Protection Coordinator must have direct access to the IG to accomplish such responsibilities. The bill also expands the responsibilities of the Council on the Inspectors General on Integrity and Efficiency to include the following: facilitating the work of the Whistleblower Protection Coordinators; and developing best practices for promoting the timely and appropriate handling and consideration of protected disclosures, allegations of reprisal, and other matters. Finally, the bill adds reporting requirements for semiannual reports. Specifically, with respect to instances of whistle-blower retaliation by an official, an Office of Inspector General must report on (1) the actual consequences imposed on the official who engaged in retaliation, and (2) whether a settlement agreement was entered with that official.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2023 · second_quarter · Health Issues
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Client expense: $370,000 · Firm income: Not reported
Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 340.
Motion to reconsider laid on the table Agreed to without objection.
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H1417-1418)
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H1417-1418)
DEBATE - The House proceeded with forty minutes of debate on H.R. 4043.
Considered under suspension of the rules. (consideration: CR H1417-1418)
Mr. Blum moved to suspend the rules and pass the bill, as amended.
Placed on the Union Calendar, Calendar No. 380.
Reported (Amended) by the Committee on Oversight and Government Reform. H. Rept. 115-510.
Congress.gov source codes: 5000, H12200
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2023 · fourth_quarter · Health Issues
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Health Equity Issues (Diversity in Clinical Trials) H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Shortage Reporting Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Client expense: $380,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2023 · third_quarter · Health Issues
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions Health Equity Issues (Diversity in Clinical Trials) H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Client expense: $330,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2023 · second_quarter · Health Issues
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Client expense: $430,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2023 · first_quarter · Health Issues
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act HR 5394 Registry Access to Medicare Claims Data includes Coverage with Evidence Development provisions H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Emerging Signals Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Client expense: $430,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act HR 5394 Registry Access to Medicare Claims Data includes Coverage with Evidence Development provisions H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Emerging Signals Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Client expense: $350,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Health Issues
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act HR 5394 Registry Access to Medicare Claims Data includes Coverage with Evidence Development provisions H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Emerging Signals Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development
Client expense: $310,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Health Issues
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act HR 5394 Registry Access to Medicare Claims Data includes Coverage with Evidence Development provisions H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Emerging Signals Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development
Client expense: $330,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Health Issues
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Medicare Coverage for Innovative Technologies (MCIT) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act HR 5394 Registry Access to Medicare Claims Data includes Coverage with Evidence Development provisions H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Emerging Signals Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development
Client expense: $260,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Ordered to be Reported (Amended) by Voice Vote.
Committee Consideration and Mark-up Session Held.
Referred to the House Committee on Oversight and Government Reform.
Introduced in House
Congress.gov source codes: 1000, Intro-H
| October 12, 2017 |